scispace - formally typeset
D

Dan W. Rurak

Researcher at University of British Columbia

Publications -  101
Citations -  2757

Dan W. Rurak is an academic researcher from University of British Columbia. The author has contributed to research in topics: Fetus & Pregnancy. The author has an hindex of 26, co-authored 101 publications receiving 2660 citations. Previous affiliations of Dan W. Rurak include Boston Children's Hospital & St. Joseph Hospital.

Papers
More filters
Journal ArticleDOI

Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.

TL;DR: While transient neonatal symptoms were found in infants after single-agent prenatal exposure to SSRIs, the addition of clonazepam appeared to alter paroxetine metabolism, leading to increased drug levels and risk for transient Neonatal symptoms.
Journal ArticleDOI

Sildenafil citrate therapy for severe early-onset intrauterine growth restriction.

TL;DR: Please cite this paper as: von Dadelszen P, Dwinnell S, Magee LA, Carleton BC, Gruslin A, Lee B, Lim KI, Liston RM, Miller SP, Rurak D, Sherlock RL, Skoll MA, Wareing MM, Baker PN, for the Research into Advanced Fetal Diagnosis and Therapy (RAFT) Group.
Journal ArticleDOI

Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure

TL;DR: Blunted facial-action responses were observed among infants with prenatal SSRI exposure alone, whereas both prenatal and postnatal exposure was associated with reduced parasympathetic withdrawal and increased parasyMPathetic cardiac modulation during recovery after an acute noxious event.
Journal ArticleDOI

Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response.

TL;DR: Prolonged prenatal SSRI exposure appears to be associated with reduced behavioral pain responses and increased parasympathetic cardiac modulation in recovery following an acute neonatal noxious event.
Journal ArticleDOI

Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding

TL;DR: Fetal and infant exposure to fluoxetine and norfluoxetines is enhanced by their stereoselective disposition in the mother, foetus, breast milk and infant, resulting in greater exposure of the foetus and infants to the biologically active enantiomers, particularly S-norfluoxETine.